REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations

被引：0
|
作者：
Yu, Helena Alexandra
Besse, Benjamin
Nishio, Makoto
Cheng, Ying
Wei, Li
Wacheck, Volker
Heymach, John
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[4] Jilin Canc Hosp, Changchun, Peoples R China
[5] Taiho Oncol Inc, Princeton, NJ USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8671
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical and real-world outcomes in patients with epidermal growth factor receptor (EGFR) exon 20 insertions in non-small cell lung cancer (NSCLC): A meta-analysis
    Tomaras, D.
    Lin, H. M.
    Forsythe, A.
    Crossland, V.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2020, 31 : S871 - S871
  • [22] Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States
    Cao, Yingdan
    Yi, Hongbin
    Shi, Fenghao
    Wei, Xiaoxia
    Han, Sheng
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, : 1335 - 1344
  • [23] Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
    Yang, Guang-Jian
    Li, Jun
    Xu, Hai-Yan
    Sun, Yang
    Liu, Liu
    Li, Hong-Shuai
    Yang, Lu
    Zhang, Yuan
    Li, Guo-Hui
    Wang, Yan
    LUNG CANCER, 2021, 152 : 39 - 48
  • [24] Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)
    Christopoulos, P.
    Prawitz, T.
    Hong, J-L.
    Lin, H. M.
    Hernandez, L.
    Jin, S.
    Tan, M.
    Proskorovsky, I.
    Lin, J.
    Zhang, P.
    Patel, J.
    Ou, S-H. I.
    Thomas, M.
    Stenzinger, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S49 - S49
  • [25] Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients
    Xu, Yuyin
    Jia, Liqing
    Jiang, Ling
    Wang, Haochen
    Jiang, Lin
    Feng, Xu
    Wei, Ran
    Yao, Qianlan
    Ren, Min
    Xue, Tian
    Li, Yuan
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Bai, Qianming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 986 - 997
  • [26] The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations
    Hernandez, Luis
    Young, Melanie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (02): : 172 - 186
  • [27] Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients
    Malapelle, Umberto
    Pilotto, Sara
    Reale, Maria Lucia
    Passiglia, Francesco
    Pisapia, Pasquale
    Pepe, Francesco
    Belluomini, Lorenzo
    Galetta, Domenico
    Cortinovis, Diego
    Tiseo, Marcello
    Passaro, Antonio
    Seminati, Davide
    Pagni, Fabio
    Parra, Hector Soto
    Migliorino, Maria Rita
    Rocco, Danilo
    Troncone, Giancarlo
    Novello, Silvia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 169
  • [28] Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
    Loong, H. H. F.
    Daniele, G.
    Yang, T-Y.
    Leal, T. A.
    Goto, K.
    Shinno, Y.
    Nishino, K.
    Sakamoto, T.
    Felip, E.
    Ruffinelli, J. C.
    Gallot, N.
    Wang, Z.
    Chen, C.
    Brennan, B.
    Pu, S-F.
    Kornacker, M.
    Grassi, P.
    Le, X.
    Tan, D. S. W.
    Goh, B-C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [29] Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
    Zwitter, Matjaz
    Rajer, Mirjana
    Stanic, Karmen
    Vrankar, Martina
    Doma, Andrej
    Cuderman, Anka
    Grmek, Marko
    Kern, Izidor
    Kovac, Viljem
    CANCER BIOLOGY & THERAPY, 2016, 17 (08) : 833 - 839
  • [30] Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art
    Fabrizio, Federico Pio
    Attili, Ilaria
    de Marinis, Filippo
    CANCERS, 2024, 16 (07)
12345